Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure

Kazuya Kato a,⁎, Kazuhiko Onodera b, Yoshiaki Iwasaki c, Minoru Matsuda d, Takako Kawakami d, Mineko Higuchi a, Kimitaka Kato a, Yurina Kato a, Masahiko Taniguchi e, Hiroyuki Furukawa e

a Department of Surgery, Pippu Clinic, 2-10, 1 cyome Nakamachi, Pippu Town Kamikawa-Gun, Hokkaido, 078-0343, Japan
b Department of Surgery, Sapporo Hokuyu Hospital, 5-1, 6-6 Higashi-Sapporo, Shiroishi-Ku, Sapporo City 003-0006, Japan
c Department of Gastroenterology and Hepatology, Okayama University, 2-5-1 Shikata Town, Okayama 700-8558, Japan
d Department of Surgery, Nihon University, 1-8-13 Surugadai Kanda, Chiyoda-Ku, Tokyo 010-8309, Japan
e Department of Surgery, Asahikawa Medical University, 1-1, 2-1 Midorigaoka, Asahikawa City 078-8510, Japan

Abstract

INTRODUCTION: Rhabdomyolysis associated with the use of pravastatin has been demonstrated to be a rare but potentially life-threatening adverse effect of statins. Here, we report a rare case of rhabdomyolysis and purpura fulminans in a patient who had used pravastatin and developed chronic renal failure (CRF) necessitating the initiation of dialysis.

PRESENTATION OF CASE: We present the case of an 86-year-old man with chronic kidney disease (CKD) treated with dialysis who was admitted with back pain. He was prescribed and took pravastatin for almost 3 years to treat hyperlipidemia. He received hemodialysis therapy 7 times prior to presentation. Laboratory values included a serum creatine concentration of 6.6 mg/dl and a creatinine phosphokinase (CPK) concentration of 2350 IU/L. An abdominal computed tomography scan showed swollen muscles with reduced muscle density and air density in the multifidus muscle. Two days after admission, he had large, tender ecchymotic lesions and purpuric progressive skin necrosis over the back, abdomen, and upper and lower extremities. The patient died 6 days after the initial admission due to disseminated intravascular coagulation (DIC). Based on these findings and the clinical history, a diagnosis of pravastatin-induced rhabdomyolysis and purpura fulminans was made.

DISCUSSION: The long-term use of statin therapy and the initiation of dialysis therapy due to ESRD, followed by a rapid onset of rhabdomyolysis within 6 days, is indicative of an elevated statin concentration. Therefore, we report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura fulminans with DIC. Based on these findings and the clinical history, a diagnosis of pravastatin-induced rhabdomyolysis and purpura fulminans was made.

CONCLUSION: We report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura fulminans with DIC in a patient with CRF.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The ability of statins to reduce the risk of cardiovascular morbidity and mortality in patients with dyslipidemia is well established [1]. In general, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are well tolerated by most users [2]. Statins are also associated with rhabdomyolysis, which may raise concerns about possible adverse drug interactions. The typical clinical presentation of rhabdomyolysis includes muscle weakness, myalgias and dark-colored urine due to myoglobinuria. The diagnosis is usually based on elevated serum skeletal muscle enzyme levels [3]. Purpura fulminans is an acute illness characterized by rapidly progressive dermal vascular thrombosis and disseminated intravascular coagulation (DIC), leading to hemorrhagic skin necrosis and soft tissue necrosis.

We report an extremely rare case of rhabdomyolysis of the multifidus muscle with pravastatin monotherapy in a patient with chronic renal failure (CRF) that may have resulted in purpura fulminans with DIC. Here, we report this rare case and review the related literature.

2. Presentation of case

The patient was an 86-year-old man with chronic kidney disease (CKD) who also had hyperlipidemia. His past medical history was significant for pravastatin treatment (10 mg once daily) for...
almost 3 years. He was diagnosed with end stage renal disease (ESRD) and started hemodialysis three times per week. He received hemodialysis therapy 7 times before presentation. Before the initiation of dialysis therapy, the patient’s serum creatinine was 4.7 mg/dL, urea 122 mmol/L, and the thyroid-stimulating hormone concentration and liver function were within normal limits. Past medical history included the following pertinent negatives: no recent viral illness, history of trauma, or epilepsy, and the absence of any other medications that could potentially be associated with rhabdomyolysis. Upon admission, the patient had generalized muscle pain and back pain and the following laboratory values: white blood cell count, 7800 mm$^3$; platelet count, 28,000 μL; Aspartate aminotransferase (AST), 77 U/L; alanine aminotransferase (ALT), 22 U/L; LDH, 356 U/L; triglycerides, 107 mg/dL; total cholesterol, 119 mg/dL; myoglobin, 3000 μg/mL; creatine, 3000 μg/mL; and creatinine phosphokinase (CPK), 2350 IU/L. The elevated CPK was not cardiac in origin because both electrocardiography and myocardial enzymes markers were within normal limits. Lab values demonstrated evidence of disseminated intravascular coagulation (DIC) and were as follows: prothrombin time, 18.3 s; active partial prothrombin time, 38.5 s; fibrinogen degradation product, 24.1 μg/mL; and D-dimer, 12.9 mg/mL. Two days after admission, he had large, tender ecchymotic lesions and purpuric, progressive skin necrosis over the back, abdomen, and upper and lower extremities. An abdominal computed tomography (CT) scan showed swollen muscles with reduced muscle density and air density in the multifidus muscle (Fig. 1 a and b) [4]. No calcification was observed in the multifidus muscle. These findings, along with the clinical history, confirmed a diagnosis of pravastatin-induced rhabdomyolysis with purpura fulminans. The patient died 6 days after the initial admission due to DIC (Fig. 2a and b).

3. Discussion

The most noteworthy adverse reactions associated with statins are elevations in myopathy and rhabdomyolysis, which is characterized by massive muscle necrosis, myoglobinuria, and acute renal failure [5]. In a recently published review, it was suggested that myopathy occurred in 20% of patients receiving statin therapy [6]. The risk of rhabdomyolysis with statin monotherapy is dose related [7,8]. The adverse events submitted to the FDA, including myalgia, rhabdomyolysis, an increase in CPK level and other muscular events, were associated with pravastatin, simvastatin, atorvastatin, and rosuvastatin. These events were more noteworthy for rosuvastatin than pravastatin and atorvastatin [9]. Acute renal failure was also associated with all 4 statins [9].

The clinical manifestations of rhabdomyolysis associated with statins are nonspecific. This condition presents as myalgias, weakness, fatigue, and dark-colored urine, which usually develop within a few days of starting the treatment. Pravastatin monotherapy is associated with the potentially fatal side effect of rhabdomyolysis, which induces DIC and purpura fulminans in our case. Rhabdomyolysis associated with pravastatin monotherapy is extremely rare and may result in myoglobinuria with acute renal failure.

Several factors have been identified that increase the risk for both myopathy and rhabdomyolysis, including advanced age, CRF, metabolic disorders, major surgery, and alcohol abuse [10–12]. Statins are safe and valuable drugs in patients with renal insufficiency. However, it may be prudent to limit the dose of pravastatin (<20 mg/day) as well as simvastatin (<10 mg/day) in patients with a GFR below 10 mL/min and prior to dialysis [13]. The side effects of statin treatment include gastrointestinal complaints, gallstones, and skin reactions, all of which are tolerable and reversible.
The mechanism of rhabdomyolysis with statins is poorly defined. The occurrence is known to increase with dose concentration [7,8]. Sakamoto [14] suggested that fluvastatin and pravastatin induced the formation of numerous vacuoles in the myofibers after 72 h of treatment in rats and inactivation of Rab GTPase, which is involved in intracellular membrane transport and is a crucial factor in statin-induced-morphological abnormality in the skeletal muscle fibers. This risk increases in patients taking concomitant drugs that inhibit the cytochrome P450 (mainly CYP2C9 or CYP3A4)-related statin metabolism such as azole antifungals, cyclosporine, fibrates, macrolides, and non-dihydropyridine calcium channel blockers [14,15]. Although pravastatin is primary eliminated by sulfation, all other available statins are metabolized by the CYP system [15–17]. The metabolic processes include phase I oxidation (mediated by CYP) isoenzymes and phase II glucuronidation (mediated by UDP-glucuronosyl transferase). Pravastatin has no phase metabolism and is minimally metabolized by phase II glucuronidation. Most statins are eliminated through biliary excretion; however, pravastatin is partially eliminated by renal excretion. Inhibition of statin metabolism (Phase I or II) and/or active membrane transport may result in elevated statin concentration and has the potential to increase the risk for statin-related adverse events. In our case, the long-term use of statin therapy and the initiation of dialysis therapy due to ESRD, followed by a rapid onset of rhabdomyolysis within 6 days, is indicative of an elevated statin concentration. However, experience with this situation is limited, particularly in a patient with severe impairment of renal function requiring dialysis. It is thought that drug or metabolic accumulation is a crucial factor involved in intracellular membrane transport and is a potential factor in the development of DIC [19]. The combination of widespread gangrene and laboratory evidence of DIC confirmed the diagnosis of purpura fulminans in our case. In dialysis patients, the situation is different and the risk of drugs and metabolite accumulation is most likely more severe. To the best of our knowledge, this is the first report of pravastatin monotherapy resulting in rhabdomyolysis of the multifidus muscle and purpura fulminans with DIC.

In summary, pravastatin monotherapy is associated with the potentially fatal side effect of rhabdomyolysis in a patient with chronic renal failure. We report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura fulminans with DIC in a patient with CRF. Early diagnosis and treatment are essential to improve the outcome. Diagnosis requires a high degree of clinical suspicion.

Conflicts of interest
None of the authors have identified a conflict interest.

Sources of funding
No funds supported this study.

Consent
Written informed consent was obtained from the patient’s relatives for publication of this manuscript and any accompanying images. Copies of the written consent are available for review by the Editor-in-Chief of this journal.

Author contributions
Dr. Kato had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Study concept and design: Kato, Sasahara, Onodera.

Acquisition of data: Kato, Ki, Taniguchi, Kawakami.

Analysis and interpretation of data: Kato, Sasahara.

Drafting of the manuscript: Kato, Furukawa.

Critical revision of the manuscript for important intellectual content: Kato, Matsuda.

Administrative, technical, or material support: Sasahara, Higuchi.

Study supervision: Onodera, Furukawa.

Key learning point
• Pravastatin monotherapy is associated with the potentially fatal side effect of rhabdomyolysis in a patient with chronic renal failure.

References
[1] Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial, Lancet, 360 (2002) 7–22.
[2] R. Lane, M. Phillips, Rhabdomyolysis, BMJ 327 (2003) 115–116.
[3] J. Sauret, G. Marinides, G. Wnag, Rhabdomyolysis, Am. Fam. Phys. 65 (2002) 907–912.
[4] T.J. Barlou, C.K. Zachar, K.L. Harkens, et al., Rhabdomyolysis: computed tomography findings, J. Comput. Assisted Tomogr. 12 (1988) 193–195.
[5] D. William, J. Freely, Pharmacokinetic-pharmacodynamic drug dynamic interactions with HMG-CoA reductase inhibitors, Clin. Pharmacokinet. 41 (2002) 343–370.
[6] S. Fernandez, E.S. Spatz, C. Jabelecki, et al., Statin myopathy: a common dilemma not reflected in clinical trials, Cleve. Clin. J. Med. 78 (2011) 393–403.
[7] B. Ricuarte, A. Guiguis, H.C. Taylor, et al., Simvastatin-amicodarone interaction resulting in rhabdomyolysis azotemia, Ann. Pharmacother. 40 (2006) 735–757.
[8] D. Graham, J.A. Staffa, D. Shatin, et al., Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs, JAMA 292 (2004) 2585–2590.
[9] T. Sakaeda, K. Kadoyama, Y. Okuno, Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system, PLoS One 6 (2011) e28124.
[10] T. Mochizuki, W.N. Tauxe, Perper technetium-99m MDP scintigraphy of rhabdomyolysis induced by exertional heart stroke: a case report, Ann. Nucl. Med. 4 (1990) 111–113.
[11] L.M. Lidmer, P. Chandeyryseon, W.F. Barth, et al., Diphosphonate bone scan in an unusual case of rhabdomyolysis: a report and literature review, J. Rheumatol. 20 (1993) 382–384.
[12] Khan F.Y. Rhabdomyolysis, A review of he literature, Neth. J. Med. 67 (2009) 272–283.
[13] G. Biesenbach, O. Janko, U. Stuby, et al., Myoglobinuric renal failure due to fluoxastatin and pravastatin-induced vaculization in rat skeletal myofibers, FASEB 21 (2007) 4087–4094.
[14] S. Bellotta, R. Paoletti, A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (23 Suppl 1) (2004) 11150–11157.
[16] A. Ginelle, D. Pharm, D. James, et al., Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin amiodarone and atazanavir, JABFM 20 (2007) 411–416.

[17] C. Rowan, A.D. Brinker, P. Nourjah, et al., Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors, Pharmacoepidemiol. Drug Saf. 18 (2009) 301–309.

[18] A.E. Lamminen, P.E. Heikali, E. Tiula, et al., Acute rhabdomyolysis: evaluation with magnetic resonance imaging compared with computed tomography and ultrasonography, Br. J. Radiol. 62 (1989) 326–330.

[19] K. Johansen, S.T. Hansen, Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis, Am. J. Surg. 165 (1993) 624–645.